New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:47 EDTSHLD, MCK, MYL, PFE, LMCA, BF.A, VTR, FOXA, MHFI, ACT, TWC, BEAM, DTV, TGT, CAKFY, NDAQ, VRX, CHTR, BF.B, HCNOn the Fly: Periodicals Wrap
WSJ: DirecTV (DTV) wants Weather Channel fee reduction as apps take hold...Brown-Forman (BF.A, BF.B) may benefit from Beam (BEAM) deal...REUTERS: Malone (LMCA, CHTR) seeks consolidation in Time Warner Cable (TWC) bid...Pfizer's (PFE) generics unit attracts several suitors (VRX, ACT, MYL)...Nasdaq (NDAQ), S&P (MHFI) interested in acquisitions to grow index businesses...BLOOMBERG: McKesson (MCK) considers JV following failure of Celesio (CAKFY) bid...Fox (FOXA) won't participate in network TV’s pilot season...Sears (SHLD) may be cut by S&P...OTHER NEWS: Target's (TGT) problems may benefit security firms, NY Times reports...Ventas (VTR) and Health Care REIT (HCN) held talks, dealReporter reports.
News For B;BEAM;LMCA;CHTR;TWC;PFE;VRX;ACT;MYL;NDAQ;MHFI;MCK;CAKFY;FOXA;SHLD;TGT;VTR;HCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
May 11, 2015
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
14:27 EDTMYLCowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
12:51 EDTACTOn The Fly: Top stock stories at midday
Subscribe for More Information
11:53 EDTMYLTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTTGTLowe's acquires leases of 13 former Target stores in Canada
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
08:26 EDTFOXAFox says 'American Idol' to end after season 15, NY Times reports
Subscribe for More Information
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
06:33 EDTFOXATV networks worried amid tough competition from digital outlets, NY Times says
Subscribe for More Information
06:01 EDTMYLStocks with implied volatility movement; MYL NOK
Stocks with implied volatility movement; Mylan (MYL) 43, Nokia (NOK) 34 according to iVolatility.
May 10, 2015
19:25 EDTACTCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
18:05 EDTFOXAFCC contract ruling may speed review of AT&T-DirecTV merger, WSJ says
Subscribe for More Information
17:45 EDTTGTJudge allows $19M Target data breach settlement to move ahead, Reuters says
Subscribe for More Information
16:06 EDTCHTR, TWCCharter seeking up to $30B to finance potential Time Warner deal, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use